Allergan, an AbbVie Inc. announced the U.S Food and Drug Administration (FDA) approval to expand the label of botox to include eight more muscles to treat adults with upper limb spasticity. The new approval was significant as it treated disabling neurological conditions influencing the quality of life of a patient.
Ipsen Group declared that Dysport, a clostridium botulinum type A toxin-haemagglutinin complex received the U.S. FDA. Dysport is the first UK botulinum toxin to get approved for pediatric spasticity therapy in upper and lower limbs.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?